Literature DB >> 22992831

PEGylated multi-walled carbon nanotubes for encapsulation and sustained release of oxaliplatin.

Linlin Wu1, Changjun Man, Hong Wang, Xiaohe Lu, Qinghai Ma, Yu Cai, Wanshan Ma.   

Abstract

PURPOSE: To develop PEGylated multi-walled carbon nanotubes as a sustained release drug delivery system.
METHODS: Oxaliplatin was incorporated into inner cavity of PEGylated multi-walled carbon nanotubes (MWCNT-PEG) using nano-extraction. Oxaliplatin release rates from MWCNT-PEG-Oxaliplatin were investigated using dialysis tubing. Cytotoxicity of oxaliplatin, MWCNT-Oxaliplatin and MWCNT-PEG-Oxaliplatin were evaluated in HT29 cell by MTT assay, Pt-DNA adducts formation, γ-H2AX formation and cell apoptosis assay.
RESULTS: Loading of oxaliplatin into MWCNT-PEG was ~43.6%. Sustained release occurred to MWCNT-PEG-Oxaliplatin, with only 34% of oxaliplatin released into medium within 6 h. In MTT assay, MWCNT-PEG-Oxaliplatin showed slightly decreased cytotoxic effect when cell viability was assessed at 12 and 24 h. A drastic increase of cytotoxicity was found when cell viability was assessed at 48 and 96 h. Pt-DNA adducts formation, γ-H2AX formation and cell apoptosis assay results showed the same trend as the MTT assay, suggesting sustained-release for MWCNT-Oxaliplatin and MWCNT-PEG-Oxaliplatin formulations.
CONCLUSIONS: PEGylated multi-walled carbon nanotubes can be used as sustained release drug delivery system, thus remarkably improving cytotoxicity of oxaliplatin on HT-29 cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22992831     DOI: 10.1007/s11095-012-0883-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  34 in total

Review 1.  Oxaliplatin: a review of evolving concepts.

Authors:  Sridhar Mani; Martin A Graham; David B Bregman; Percy Ivy; Stephen G Chaney
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

2.  Carbon nanohorns as anticancer drug carriers.

Authors:  Kumiko Ajima; Masako Yudasaka; Tatsuya Murakami; Alan Maigné; Kiyotaka Shiba; Sumio Iijima
Journal:  Mol Pharm       Date:  2005 Nov-Dec       Impact factor: 4.939

3.  Oops they did it again! Carbon nanotubes hoax scientists in viability assays.

Authors:  J M Wörle-Knirsch; K Pulskamp; H F Krug
Journal:  Nano Lett       Date:  2006-06       Impact factor: 11.189

4.  Synthesis and characterization of water soluble single-walled carbon nanotube graft copolymers.

Authors:  Bin Zhao; Hui Hu; Aiping Yu; Daniel Perea; Robert C Haddon
Journal:  J Am Chem Soc       Date:  2005-06-08       Impact factor: 15.419

Review 5.  Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.

Authors:  Stephen G Chaney; Sharon L Campbell; Ekaterina Bassett; Yibing Wu
Journal:  Crit Rev Oncol Hematol       Date:  2005-01       Impact factor: 6.312

6.  Oxaliplatin: a review in the era of molecularly targeted therapy.

Authors:  T Alcindor; N Beauger
Journal:  Curr Oncol       Date:  2011-01       Impact factor: 3.677

7.  Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks.

Authors:  Arkady Celeste; Oscar Fernandez-Capetillo; Michael J Kruhlak; Duane R Pilch; David W Staudt; Alicia Lee; Robert F Bonner; William M Bonner; André Nussenzweig
Journal:  Nat Cell Biol       Date:  2003-07       Impact factor: 28.824

8.  Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy.

Authors:  Neelam Taneja; Mandel Davis; John S Choy; Michael A Beckett; Rachana Singh; Stephen J Kron; Ralph R Weichselbaum
Journal:  J Biol Chem       Date:  2003-10-15       Impact factor: 5.157

9.  Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells.

Authors:  Shu-Jun Chiu; Jui-I Chao; Yi-Jang Lee; Tzu-Sheng Hsu
Journal:  Toxicol Lett       Date:  2008-05-21       Impact factor: 4.372

10.  Evaluation of in vitro chemosensitivity of antitumor drugs using the MTT assay in fresh human breast cancer.

Authors:  J M Xu; S T Song; Z M Tang; X Q Liu; Z F Jiang; L Zhou; Y B Li; Y Huang
Journal:  Breast Cancer Res Treat       Date:  1998-06       Impact factor: 4.872

View more
  5 in total

Review 1.  Basics to advances in nanotherapy of colorectal cancer.

Authors:  Ankita Tiwari; Shivani Saraf; Ankit Jain; Pritish K Panda; Amit Verma; Sanjay K Jain
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

2.  Hyaluronate Functionalized Multi-Wall Carbon Nanotubes Filled with Carboplatin as a Novel Drug Nanocarrier against Murine Lung Cancer Cells.

Authors:  Daniel Salas-Treviño; Odila Saucedo-Cárdenas; María de Jesús Loera-Arias; Humberto Rodríguez-Rocha; Aracely García-García; Roberto Montes-de-Oca-Luna; Edgar I Piña-Mendoza; Flavio F Contreras-Torres; Gerardo García-Rivas; Adolfo Soto-Domínguez
Journal:  Nanomaterials (Basel)       Date:  2019-11-06       Impact factor: 5.076

3.  PEGylated Chitosan Nanoparticles Encapsulating Ascorbic Acid and Oxaliplatin Exhibit Dramatic Apoptotic Effects against Breast Cancer Cells.

Authors:  Sherif Ashraf Fahmy; Asmaa Ramzy; Asmaa A Mandour; Soad Nasr; Anwar Abdelnaser; Udo Bakowsky; Hassan Mohamed El-Said Azzazy
Journal:  Pharmaceutics       Date:  2022-02-13       Impact factor: 6.321

Review 4.  Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy.

Authors:  Buhle Buyana; Tobeka Naki; Sibusiso Alven; Blessing Atim Aderibigbe
Journal:  Int J Mol Sci       Date:  2022-09-24       Impact factor: 6.208

5.  Application of Poly (Agar-Co-Glycerol-Co-Sweet Almond Oil) Based Organo-Hydrogels as a Drug Delivery Material.

Authors:  Tuba Ersen Dudu; Duygu Alpaslan; Nahit Aktas
Journal:  J Polym Environ       Date:  2021-06-22       Impact factor: 3.667

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.